drugset
drugset / Trial / NCT02148185

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease

NCT02148185 ↗

Phase 1 Completed 1 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate PK, PD and safety of a single oral dose of MT-1303 in subjects with Crohn's disease.

Timeline

Start
2014-05
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject amiselimod Small molecule — Oral

Indications

Crohn disease